Abstract
69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have